Pharma

Your Article Summary

See Latest Articles

Gilead Sciences Receives Subpoena from U.S. Department of Health and Human Services Regarding Ranexa
Gilead, 08/17/09

Gilead Sciences, Inc. announced that it has received a subpoena from the Office of the Inspector General of the Department of Health and Human Services requesting documents regarding the development, marketing and sales of Ranexa (ranolazine). Ranexa is approved for the treatment of chronic angina and was developed and originally commercialized by CV Therapeutics, a company that Gilead acquired in April 2009.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR
Abbott, 12/11/09

Recombinant Human Erythropoietin, Epogin Injection Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09

Synthon announces European approvals for Raloxifene
Synthon, 12/08/09

 See all of Drug/Product Approvals